Clinical trial
A Open Label, Post Marketing Surveillance Study Following Transfusion of INTERCEPT Platelet Components
NCT02549222
Study timeline
Study start (actual)2015-12-01Date precision: month
Registry last updated2022-02-18
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Transfusion Related Acute Lung Injuryunresolved
Interventions
Standard of CareOTHER
Sponsors & collaborators
Cerus Corporationlead sponsor
Mapped research locations
New YorkNew York, United States1BostonMassachusetts, United States1Los AngelesCalifornia, United States1BaltimoreMaryland, United States1St LouisMissouri, United States1AtlantaGeorgia, United States1NashvilleTennessee, United States1CincinnatiOhio, United States1DurhamNorth Carolina, United States1MinneapolisMinnesota, United States1RochesterNew York, United States1New HavenConnecticut, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02549222 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.